Onvansertib received Fast Track Designation from the FDA in 2020 for KRAS-mutated mCRC treatment, and recent positive data from Cardiff Oncology highlights its potential in ongoing trials for metastatic pancreatic ductal adenocarcinoma (mPDAC) and small-cell lung cancer (SCLC) [27]. Here, KRAS is linked to small cell lung carcinoma.